Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.
Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.
复制标题
DOI：
10.1007/s10147-018-1250-2
复制
发表时间：
2018-08
影响因子：
3.3
通讯作者：
Nomura S
中科院分区：
文献类型：
--
作者：
Nakaya A;Kurata T;Yoshioka H;Takeyasu Y;Niki M;Kibata K;Satsutani N;Ogata M;Miyara T;Nomura S
存在未满足的需要来鉴定预测非小细胞肺癌（NSCLC）患者中对纳武单抗的响应的标志物。嗜中性粒细胞与淋巴细胞比率（NLR）最近被认为是各种癌症患者预后不良的指标。在本研究中，我们量化了NLR对接受nivolumab治疗的NSCLC患者的预测影响。我们回顾性分析了2015年12月至2016年12月在关西医科大学医院接受nivolumab治疗的101例晚期NSCLC患者。患者每2周以3 mg/kg的剂量施用纳武单抗。评估了NLR在治疗前和纳武利尤单抗治疗后2周和4周对疾病进展的预测价值。治疗前NLR < 3的患者的中位无进展生存期（PFS）为3.4个月，而NLR ≥ 3的患者为2.9个月（p = 0.484）。治疗后2周NLR < 3的患者的中位PFS为5.3个月，而NLR ≥ 3的患者为2.1个月（p = 0.00528）。治疗后4周NLR < 3的患者的中位PFS为5.3个月，而NLR ≥ 3的患者的中位PFS为2.0个月（p = 0.00515）。治疗后2周和4周的NLR可能是预测接受纳武利尤单抗治疗的晚期NSCLC患者的治疗反应或疾病进展的有用标志物。
There is an unmet need to identify markers that predict the response to nivolumab in patients with non-small-cell lung cancer (NSCLC). The neutrophil-to-lymphocyte ratio (NLR) was recently recognized as an indicator of a poor prognosis in patients with various cancers. In the present study, we quantified the predictive impact of NLR in patients with NSCLC treated with nivolumab. We retrospectively analyzed 101 patients with advanced NSCLC treated with nivolumab at Kansai Medical University Hospital from December 2015 to December 2016. Patients were administered nivolumab at a dose of 3 mg/kg every 2 weeks. The predictive value of NLR for disease progression before treatment and 2 and 4 weeks after nivolumab treatment was assessed. The median progression-free survival (PFS) of patients with an NLR of < 3 before treatment was 3.4 months, whereas that of patients with an NLR of ≥ 3 was 2.9 months (p = 0.484). The median PFS of patients with an NLR of < 3 at 2 weeks after treatment was 5.3 months, whereas that of patients with an NLR of ≥ 3 was 2.1 months (p = 0.00528). The median PFS of patients with an NLR of < 3 at 4 weeks after treatment was 5.3 months, whereas that of patients with an NLR of ≥ 3 was 2.0 months (p = 0.00515). The NLR at 2 and 4 weeks after treatment might be a useful marker for the prediction of the treatment response or disease progression in patients with advanced NSCLC receiving nivolumab.
登录
查看更多内容
DOI：
10.1038/nrc3239
发表时间：
2012-03-22
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Pardoll DM
通讯作者：
Pardoll DM
基线嗜中性粒细胞与淋巴细胞比率与经ipilmimab治疗的转移性黑色素瘤患者的结果有关。
影响因子：
8.8
作者：
Ferrucci PF;Gandini S;Battaglia A;Alfieri S;Di Giacomo AM;Giannarelli D;Cappellini GC;De Galitiis F;Marchetti P;Amato G;Lazzeri A;Pala L;Cocorocchio E;Martinoli C
通讯作者：
Martinoli C
影响因子：
4.5
作者：
Dalpiaz, Orietta;Ehrlich, Georg C.;Hutterer, Georg C.
通讯作者：
Hutterer, Georg C.
影响因子：
3.4
作者：
Cedres, S.;Torrejon, D.;Felip, E.
通讯作者：
Felip, E.
影响因子：
3.8
作者：
Jafri SH;Shi R;Mills G
通讯作者：
Mills G